Evaxion's Upcoming Business Update and Financial Results
Evaxion A/S is set to announce a comprehensive business update along with its third quarter 2025 financial results. This important event is scheduled for the morning of November 6, 2025. As a prominent player in the TechBio space, Evaxion leverages its innovative AI-Immunology™ platform to develop next-generation vaccines that address various health concerns.
What to Expect During the Conference Call
The company's Executive Management team will host an engaging conference call, providing insights into its latest developments. This session is open to the public and encourages participation. Attendees can look forward to a detailed overview of the business update and the latest financial performance metrics.
Timing and Accessing the Call
The conference call kicks off at 14:30 CET and 08:30 EST, allowing interested parties ample opportunity to tune in. To participate, individuals should register in advance to receive the necessary dial-in details and unique PIN codes, ensuring a smooth experience when joining the call.
Webcast Details for Broader Access
For those unable to join via phone, Evaxion will provide a webcast of the event. This option allows attendees to follow along visually and engage with the information shared during the presentation. A recording of the webcast will also be made available shortly after the event on the company's website.
Connecting with Evaxion
With a commitment to transparency and communication, Evaxion provides clear avenues for stakeholders to connect with the company. Those looking for more information can reach out directly to Mads Kronborg, the Vice President of Investor Relations & Communication, at +45 53 54 82 96.
About Evaxion and Its Innovative Approach
Evaxion A/S is at the forefront of revolutionizing vaccine development through its advanced AI platform known as AI-Immunology™. The company utilizes cutting-edge AI technology to decode the complexities of the human immune system, leading to the creation of groundbreaking immunotherapies focused on cancer, bacterial diseases, and viral infections. Evaxion’s innovative pipeline includes personalized vaccines for oncology and a preclinical pipeline targeting infectious diseases with significant medical needs.
This ambitious approach not only aims to set new standards in treatment efficacy but also to transform the lives of patients around the world. Evaxion is on a mission to provide customized and effective treatment options that harness the power of AI, reflecting its commitment to addressing pressing medical challenges.
Frequently Asked Questions
When will Evaxion announce its financial results?
Evaxion will announce its financial results on November 6, 2025.
How can I participate in the conference call?
To participate, you need to register in advance to receive dial-in details and a unique PIN code.
What time does the conference call start?
The call will begin at 14:30 CET (08:30 EST).
Will there be a recording of the event available?
Yes, the webcast recording will be available shortly after the event on Evaxion's website.
Who can I contact for more information about Evaxion?
Mads Kronborg, Vice President of Investor Relations & Communication, is available for inquiries at +45 53 54 82 96.
